No Data
PAVmed Is Maintained at Buy by Ascendiant Capital
PAVmed Analyst Ratings
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
Express News | Lucid Diagnostics And Subsidiary Of PAVmed Announced That It Has Submitted Its Complete Clinical Evidence Package For Its Esoguard Esophageal DNA Test To Molecular Diagnostics Program Seeking Medicare Coverage For Esoguard Esophageal DNA Test
PAVmed Positioned for Growth Despite Q3 Revenue Miss: Buy Rating Affirmed by Anthony Vendetti
No Data
